Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.23
NYSE:PKI's Cash to Debt is ranked lower than
85% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NYSE:PKI: 0.23 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:PKI' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.29 Max: 2.06
Current: 0.23
0.09
2.06
Equity to Asset 0.50
NYSE:PKI's Equity to Asset is ranked lower than
63% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NYSE:PKI: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:PKI' s Equity to Asset Range Over the Past 10 Years
Min: 0.24  Med: 0.5 Max: 0.63
Current: 0.5
0.24
0.63
Interest Coverage 7.69
NYSE:PKI's Interest Coverage is ranked lower than
76% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NYSE:PKI: 7.69 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:PKI' s Interest Coverage Range Over the Past 10 Years
Min: 2.25  Med: 7.58 Max: 16.75
Current: 7.69
2.25
16.75
F-Score: 7
Z-Score: 3.33
M-Score: -2.54
WACC vs ROIC
7.59%
9.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.17
NYSE:PKI's Operating margin (%) is ranked higher than
79% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.53 vs. NYSE:PKI: 13.17 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:PKI' s Operating margin (%) Range Over the Past 10 Years
Min: 4.75  Med: 9.42 Max: 12.65
Current: 13.17
4.75
12.65
Net-margin (%) 10.27
NYSE:PKI's Net-margin (%) is ranked higher than
79% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. NYSE:PKI: 10.27 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:PKI' s Net-margin (%) Range Over the Past 10 Years
Min: 0.4  Med: 7.21 Max: 22.94
Current: 10.27
0.4
22.94
ROE (%) 11.25
NYSE:PKI's ROE (%) is ranked higher than
75% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.49 vs. NYSE:PKI: 11.25 )
Ranked among companies with meaningful ROE (%) only.
NYSE:PKI' s ROE (%) Range Over the Past 10 Years
Min: 0.41  Med: 7.93 Max: 22
Current: 11.25
0.41
22
ROA (%) 5.67
NYSE:PKI's ROA (%) is ranked higher than
72% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. NYSE:PKI: 5.67 )
Ranked among companies with meaningful ROA (%) only.
NYSE:PKI' s ROA (%) Range Over the Past 10 Years
Min: 0.22  Med: 4.28 Max: 12.48
Current: 5.67
0.22
12.48
ROC (Joel Greenblatt) (%) 66.80
NYSE:PKI's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.24 vs. NYSE:PKI: 66.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:PKI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 26.99  Med: 51.1 Max: 72.5
Current: 66.8
26.99
72.5
Revenue Growth (3Y)(%) 2.90
NYSE:PKI's Revenue Growth (3Y)(%) is ranked lower than
55% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. NYSE:PKI: 2.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:PKI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 2.7 Max: 17.9
Current: 2.9
-10.7
17.9
EBITDA Growth (3Y)(%) 21.00
NYSE:PKI's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NYSE:PKI: 21.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:PKI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -21  Med: 8 Max: 35.4
Current: 21
-21
35.4
EPS Growth (3Y)(%) 44.70
NYSE:PKI's EPS Growth (3Y)(%) is ranked higher than
93% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. NYSE:PKI: 44.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:PKI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -79  Med: 9.3 Max: 421.7
Current: 44.7
-79
421.7
» NYSE:PKI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

PKI Guru Trades in Q3 2015

Joel Greenblatt 41,019 sh (New)
Louis Moore Bacon 126,581 sh (New)
Ray Dalio 24,716 sh (New)
Jim Simons 391,400 sh (+470.55%)
Ken Fisher 670,227 sh (+3.68%)
Vanguard Health Care Fund Sold Out
PRIMECAP Management 3,298,124 sh (-5.10%)
Chuck Royce 1,998,330 sh (-13.85%)
» More
Q4 2015

PKI Guru Trades in Q4 2015

Steven Cohen 30,000 sh (New)
PRIMECAP Management 3,302,105 sh (+0.12%)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
Joel Greenblatt Sold Out
Ken Fisher 661,620 sh (-1.28%)
Chuck Royce 706,430 sh (-64.65%)
Jim Simons 45,500 sh (-88.38%)
» More
Q1 2016

PKI Guru Trades in Q1 2016

Paul Tudor Jones 18,020 sh (New)
PRIMECAP Management 3,497,630 sh (+5.92%)
Jim Simons Sold Out
Steven Cohen Sold Out
Chuck Royce Sold Out
Ken Fisher 655,760 sh (-0.89%)
» More
Q2 2016

PKI Guru Trades in Q2 2016

Jim Simons 29,300 sh (New)
Ray Dalio 9,100 sh (New)
Ken Fisher 685,785 sh (+4.58%)
PRIMECAP Management 3,450,105 sh (-1.36%)
Paul Tudor Jones 13,578 sh (-24.65%)
» More
» Details

Insider Trades

Latest Guru Trades with PKI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:BMXMF, NAS:QGEN, OTCPK:ERFSF, NYSE:BIO.B, NAS:DXCM, NAS:ICLR, NYSE:CRL, NAS:CPHD, NYSE:ALR, NAS:VWR, NAS:PRXL, NAS:BRKR, NAS:PRAH, OTCPK:CZMWY, NYSE:Q, NAS:INCR, NAS:NEOG, NAS:EXAS, NAS:IDXX, NAS:MYGN » details
Traded in other countries:PKN.Germany,
PerkinElmer Inc is a provider of technology, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets.

PerkinElmer Inc is a Massachusetts corporation, founded in 1947. The Company provides products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through its technologies, solutions, and services, it addresses critical issues that help to improve the health and safety of people and their environment. The Company reports its business in two segments: Human Health and Environmental Health. Its Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. Within the Human Health segment, it serves both the Diagnostics and Research Markets. In Diagnostics Markets it provides early detection for genetic disorders from pre-conception to early childhood, as well as digital x-ray flat panel detectors and infectious disease testing for the diagnostics market. In the Research market, it provides suite of solutions including reagents, liquid handling and detection and imaging technologies that enable researchers to improve the drug discovery process. Its main products for Human Health applications includes DELFIA Xpress screening platform, NeoGram, MS/MS AAAC in vitro diagnostic kit, NeoBase, Non-derivatized MS/MS kit, Specimen Gate informatics data management solution, XRD family of amorphous silicon digital x-ray flat panel detectors, Opera high content screening system and Operetta high content imaging system, UltraVIEW VoX 3D live cell imaging system and Asset Genius, an informatics-based business intelligence solution. Its Environmental Health segment provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets. Its main products Environmental Health applications includes Clarus series of gas chromatographs, Flexar series of liquid chromatography and mass spectrometry instruments and LAMBDA UV/Vis series. The Company's main brands include AlphaLISA, AlphaScreen, Asset Genius, AutoDELFIA, BACS-on-Beads, BoBs, cell:explorer, Chem3D, ChemBioOffice, ChemDraw, Columbus, Datalytix, Dexela CMOS FPDs, Elsevier's Reaxys, EnLite, Ensemble for Biology, Ensemble for Chemistry and Ensemble for QA/QC. Its customers include pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors and government agencies. It competes with foreign and domestic organizations, which produce a comprehensive array of goods and services. The Company's operations are subject to various foreign, federal, state and local safety laws.

Ratios

vs
industry
vs
history
P/E(ttm) 26.57
PKI's P/E(ttm) is ranked higher than
62% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.07 vs. PKI: 26.57 )
Ranked among companies with meaningful P/E(ttm) only.
PKI' s P/E(ttm) Range Over the Past 10 Years
Min: 5.3  Med: 26.92 Max: 3165
Current: 26.57
5.3
3165
Forward P/E 18.52
PKI's Forward P/E is ranked higher than
74% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. PKI: 18.52 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 26.70
PKI's PE(NRI) is ranked higher than
62% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.43 vs. PKI: 26.70 )
Ranked among companies with meaningful PE(NRI) only.
PKI' s PE(NRI) Range Over the Past 10 Years
Min: 11.52  Med: 27.36 Max: 2724
Current: 26.7
11.52
2724
Price/Owner Earnings (ttm) 23.22
PKI's Price/Owner Earnings (ttm) is ranked higher than
67% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.41 vs. PKI: 23.22 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PKI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.67  Med: 20.86 Max: 1169.39
Current: 23.22
4.67
1169.39
P/B 2.90
PKI's P/B is ranked higher than
63% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. PKI: 2.90 )
Ranked among companies with meaningful P/B only.
PKI' s P/B Range Over the Past 10 Years
Min: 0.88  Med: 1.86 Max: 2.97
Current: 2.9
0.88
2.97
P/S 2.72
PKI's P/S is ranked higher than
55% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. PKI: 2.72 )
Ranked among companies with meaningful P/S only.
PKI' s P/S Range Over the Past 10 Years
Min: 0.72  Med: 1.82 Max: 2.79
Current: 2.72
0.72
2.79
PFCF 22.35
PKI's PFCF is ranked higher than
59% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.85 vs. PKI: 22.35 )
Ranked among companies with meaningful PFCF only.
PKI' s PFCF Range Over the Past 10 Years
Min: 7.79  Med: 21.9 Max: 93.23
Current: 22.35
7.79
93.23
POCF 19.80
PKI's POCF is ranked lower than
53% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.84 vs. PKI: 19.80 )
Ranked among companies with meaningful POCF only.
PKI' s POCF Range Over the Past 10 Years
Min: 6.31  Med: 17.82 Max: 42.63
Current: 19.8
6.31
42.63
EV-to-EBIT 22.85
PKI's EV-to-EBIT is ranked lower than
53% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.92 vs. PKI: 22.85 )
Ranked among companies with meaningful EV-to-EBIT only.
PKI' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.6  Med: 23 Max: 59.2
Current: 22.85
10.6
59.2
EV-to-EBITDA 16.73
PKI's EV-to-EBITDA is ranked higher than
50% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.14 vs. PKI: 16.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
PKI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7  Med: 15 Max: 23.6
Current: 16.73
7
23.6
PEG 2.21
PKI's PEG is ranked higher than
56% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.70 vs. PKI: 2.21 )
Ranked among companies with meaningful PEG only.
PKI' s PEG Range Over the Past 10 Years
Min: 0.58  Med: 2.42 Max: 181.36
Current: 2.21
0.58
181.36
Shiller P/E 38.90
PKI's Shiller P/E is ranked higher than
62% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.82 vs. PKI: 38.90 )
Ranked among companies with meaningful Shiller P/E only.
PKI' s Shiller P/E Range Over the Past 10 Years
Min: 11.76  Med: 26.04 Max: 39.98
Current: 38.9
11.76
39.98
Current Ratio 1.92
PKI's Current Ratio is ranked lower than
62% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.48 vs. PKI: 1.92 )
Ranked among companies with meaningful Current Ratio only.
PKI' s Current Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.66 Max: 2.13
Current: 1.92
0.74
2.13
Quick Ratio 1.39
PKI's Quick Ratio is ranked lower than
72% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. PKI: 1.39 )
Ranked among companies with meaningful Quick Ratio only.
PKI' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.23 Max: 1.7
Current: 1.39
0.54
1.7
Days Inventory 90.15
PKI's Days Inventory is ranked higher than
50% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 90.15 vs. PKI: 90.15 )
Ranked among companies with meaningful Days Inventory only.
PKI' s Days Inventory Range Over the Past 10 Years
Min: 65.31  Med: 77.12 Max: 84.55
Current: 90.15
65.31
84.55
Days Sales Outstanding 69.68
PKI's Days Sales Outstanding is ranked lower than
56% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. PKI: 69.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
PKI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.62  Med: 75.88 Max: 79.24
Current: 69.68
61.62
79.24
Days Payable 46.39
PKI's Days Payable is ranked lower than
60% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. PKI: 46.39 )
Ranked among companies with meaningful Days Payable only.
PKI' s Days Payable Range Over the Past 10 Years
Min: 45.03  Med: 56.44 Max: 64.02
Current: 46.39
45.03
64.02

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
PKI's Dividend Yield is ranked lower than
78% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.18 vs. PKI: 0.50 )
Ranked among companies with meaningful Dividend Yield only.
PKI' s Dividend Yield Range Over the Past 10 Years
Min: 0.49  Med: 1.05 Max: 2.43
Current: 0.5
0.49
2.43
Dividend Payout 0.14
PKI's Dividend Payout is ranked higher than
94% of the 54 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. PKI: 0.14 )
Ranked among companies with meaningful Dividend Payout only.
PKI' s Dividend Payout Range Over the Past 10 Years
Min: 0.05  Med: 0.29 Max: 3.5
Current: 0.14
0.05
3.5
Forward Dividend Yield 0.50
PKI's Forward Dividend Yield is ranked lower than
76% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.14 vs. PKI: 0.50 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.50
PKI's Yield on cost (5-Year) is ranked lower than
81% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. PKI: 0.50 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PKI' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.49  Med: 1.05 Max: 2.43
Current: 0.5
0.49
2.43
3-Year Average Share Buyback Ratio 0.90
PKI's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. PKI: 0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PKI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.7  Med: 0.2 Max: 3.3
Current: 0.9
-10.7
3.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.53
PKI's Price/Projected FCF is ranked higher than
68% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. PKI: 1.53 )
Ranked among companies with meaningful Price/Projected FCF only.
PKI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.38 Max: 131.1
Current: 1.53
0.52
131.1
Price/DCF (Earnings Based) 2.49
PKI's Price/DCF (Earnings Based) is ranked lower than
63% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.98 vs. PKI: 2.49 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.49
PKI's Price/Median PS Value is ranked lower than
76% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. PKI: 1.49 )
Ranked among companies with meaningful Price/Median PS Value only.
PKI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 0.92 Max: 1.84
Current: 1.49
0.29
1.84
Price/Peter Lynch Fair Value 1.80
PKI's Price/Peter Lynch Fair Value is ranked higher than
75% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.23 vs. PKI: 1.80 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PKI' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.74  Med: 2.79 Max: 18.34
Current: 1.8
0.74
18.34
Earnings Yield (Greenblatt) (%) 4.40
PKI's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. PKI: 4.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PKI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.7  Med: 4.3 Max: 9.4
Current: 4.4
1.7
9.4
Forward Rate of Return (Yacktman) (%) 17.91
PKI's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.44 vs. PKI: 17.91 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PKI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -0.8  Med: 11.6 Max: 43.7
Current: 17.91
-0.8
43.7

More Statistics

Revenue (TTM) (Mil) $2,283
EPS (TTM) $ 2.09
Beta0.89
Short Percentage of Float2.77%
52-Week Range $39.50 - 57.28
Shares Outstanding (Mil)109.40

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,314 2,408 2,546
EPS ($) 2.79 3.00 3.40
EPS w/o NRI ($) 2.79 3.00 3.40
EPS Growth Rate
(3Y to 5Y Estimate)
4.88%
Dividends Per Share ($) 0.28 0.28 0.29
» More Articles for NYSE:PKI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Family Dollar Stores Inc, Texas Instruments Inc, Mylan Inc, and PerkinEl Feb 08 2015 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
The Best Dividends on April 18, 2012 Apr 18 2012 
PerkinElmer Inc. Reports Operating Results (10-K) Mar 01 2011 
PerkinElmer Inc. Reports Operating Results (10-Q) Nov 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) Aug 10 2010 
PerkinElmer Inc. Reports Operating Results (10-Q) May 13 2010 
PerkinElmer Inc. (PKI) Chairman, President & CEO Robert F Friel sells 150,000 Shares Dec 17 2009 
PerkinElmer Inc. Reports Operating Results (10-Q) Aug 14 2009 
PerkinElmer Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
PerkinElmer, Inc. (United States) – Value Analysis (NYSE:PKI) : September 12, 2016 Sep 12 2016
PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bullish Manner : PKI-US :... Sep 09 2016
Aspect Imaging Introduces its Cost-Effective, Top Quality, Multi-Modality Imaging Tools to... Sep 05 2016
PerkinElmer to Present at Morgan Stanley Global Healthcare Conference Sep 01 2016
ETF’s with exposure to PerkinElmer, Inc. (United States) : August 26, 2016 Aug 26 2016
PerkinElmer, Inc. (United States) breached its 50 day moving average in a Bearish Manner : PKI-US :... Aug 25 2016
PERKINELMER INC Financials Aug 13 2016
PERKINELMER INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Aug 12 2016
ETF’s with exposure to PerkinElmer, Inc. (United States) : August 11, 2016 Aug 11 2016
Parkland Fuel Corp. :PKI-CA: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 Aug 10 2016
PERKINELMER INC Files SEC form 10-Q, Quarterly Report Aug 09 2016
PerkinElmer, Inc. (United States) :PKI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9,... Aug 09 2016
PerkinElmer (PKI) Beats Q2 Earnings, FY16 View Maintained Aug 05 2016
PerkinElmer, Inc. (United States) : PKI-US: Dividend Analysis : October 14th, 2016 (record date) :... Aug 05 2016
PerkinElmer downgraded by Mizuho Aug 05 2016
Edited Transcript of PKI earnings conference call or presentation 4-Aug-16 9:00pm GMT Aug 04 2016
PerkinElmer beats 2Q profit forecasts Aug 04 2016
PerkinElmer beats 2Q profit forecasts Aug 04 2016
PerkinElmer 2nd-quarter profit edges past Street estimates Aug 04 2016
PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)